A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers.
The biotech is developing what it calls logic-gated cell …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The relationship between parental mental disorders and child school performance.
Biogen’s acquisition of HI-Bio’s anti-CD38 monoclonal antibody will expand its immunology presence. Image credit: Shutterstock / Tada Images. As Eli Lilly’s Kisunla (donanemab) enters the